Silexion Therapeutics (NASDAQ:SLXN) Stock Rating Upgraded by Zacks Research

Silexion Therapeutics (NASDAQ:SLXN) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other equities analysts have also recently weighed in on SLXN. Litchfield Hills Research began coverage on Silexion Therapeutics in a report on Monday. They issued a “buy” rating for the company. Wall Street Zen raised shares of Silexion Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $75.00.

Silexion Therapeutics Price Performance

Shares of NASDAQ SLXN opened at $2.57 on Tuesday. The stock has a market capitalization of $8.04 million, a price-to-earnings ratio of -0.23 and a beta of -0.06. Silexion Therapeutics has a 12 month low of $2.13 and a 12 month high of $51.75. The firm’s 50 day simple moving average is $3.04 and its 200-day simple moving average is $6.95. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $0.52.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.